专家分析，近期鼻病毒检测阳性率上升明显，14岁及以下病例组阳性率高于其他年龄组。南方省份呼吸 道合胞病毒检测阳性率上升明显，本周略有下降，0～4岁病例组高于其他年龄组。肠道病毒和南方省份 流感病毒检测阳性率近期小幅上升。新型冠状病毒和普通冠状病毒检测阳性率呈下降趋势。其他监测的 呼吸道病原体阳性率总体处于低水平。 总体来说，呼吸道传染病疫情处于较低水平，但呈现缓慢上升趋势。鼻病毒、呼吸道合胞病毒和肠道病 毒等存在一定水平活动。托幼机构、中小学校等重点机构人群密集，容易出现聚集性疫情，应注意防范 呼吸道传染病。 此外，检出均为已知常见病原体，没有发现未知病原体及其导致的新发传染病。 近日有报道称，上海地区不少儿童因感染呼吸道合胞病毒前往医院就诊。 随着气温降低，一些呼吸道疾病开始活跃。据疾控部门最新发布的监测数据，鼻病毒、呼吸道合胞病 毒、肠道病毒是哨点医院流感样病例呼吸道样本阳性率前三位。 总体来看，我国呼吸道传染病疫情处于较低水平，但呈现出缓慢上升趋势。 呼吸道传染病疫情呈现缓慢上升趋势 呼吸道合胞病毒是一种常见的病原体，易发于冬春季节，可引起6个月以下婴儿患细支气管炎和肺炎等 下呼吸道感染，较大儿童及成人 ...

万泰生物所属申万行业为：医药生物-生物制品-疫苗。所属概念板块包括：体外诊断、抗原检测、猴痘 概念、幽门螺杆概念、疫苗等。 截至6月30日，万泰生物股东户数3.84万，较上期增加24.00%；人均流通股32958股，较上期减少 19.36%。2025年1月-6月，万泰生物实现营业收入8.44亿元，同比减少38.25%；归母净利润-1.44亿元， 同比减少155.30%。 分红方面，万泰生物A股上市后累计派现15.41亿元。近三年，累计派现13.11亿元。 机构持仓方面，截止2025年6月30日，万泰生物十大流通股东中，香港中央结算有限公司位居第四大流 通股东，持股2275.44万股，相比上期增加515.08万股。华泰柏瑞沪深300ETF（510300）位居第九大流 通股东，持股672.44万股，相比上期增加71.58万股。易方达沪深300医药ETF（512010）位居第十大流 通股东，持股622.30万股，相比上期减少50.92万股。招商国证生物医药指数A（161726）退出十大流通 股东之列。 10月9日，万泰生物盘中上涨2.05%，截至11:01，报57.71元/股，成交1.59亿元，换手率0.22%，总 ...

Core Viewpoint - Bill Gates is making a historic commitment to donate nearly all of his wealth, approximately $100 billion, to the Gates Foundation, with the goal of eradicating preventable diseases in impoverished regions within 20 years [2][3][5]. Group 1: Philanthropic Commitment - Gates' donation is the largest charitable commitment in modern history, with the foundation expected to spend around $10 billion annually over the next 20 years, totaling over $200 billion [3][4]. - The foundation aims to eradicate four to five diseases within the next two decades, focusing on polio, malaria, tuberculosis, and HIV [4][5]. - Gates emphasizes the need for continued investment from wealthy nations to sustain progress, as many have begun to reduce foreign aid significantly [5][6][8]. Group 2: Foundation's Operational Model - The Gates Foundation operates differently from many long-standing foundations by setting a closure deadline, which Gates believes will motivate more effective spending [3][4]. - The foundation has a large workforce of over 2,000 employees, focusing on various global health and education initiatives, and has significantly increased its annual spending from $1 billion in 2000 to an expected $8.2 billion in 2024 [12][13]. - The foundation's approach combines data-driven methods from the tech industry with humanitarian efforts, creating a model that has influenced many other organizations [6][7]. Group 3: Challenges and Criticism - Gates faces criticism for his methods and the influence of the foundation, with some arguing that it undermines public institutions and promotes a specific agenda [14][15]. - The reduction of foreign aid by wealthy countries poses a significant risk to the foundation's goals, as collective action is essential for success [8][21]. - Despite criticism, Gates remains optimistic about the foundation's impact and encourages other billionaires to commit to philanthropy through initiatives like the Giving Pledge [20][21].

研究团队通过一系列实验，发现了蓝耳病病毒"作恶"的关键步骤。蓝耳病病毒感染猪肺细胞后会激活一 种特定蛋白，指挥细胞内的"骨架"重新排列，形成特殊的"脚手架"结构，并使得细胞表面的黏附"受 体"数量大增，这些受体就像一个个"登船梯"。有了"脚手架"和"登船梯"，原本难以入侵的细菌得以"搭 便车"侵入，引发严重继发感染。 业内专家认为，这项研究揭示了病毒帮助细菌入侵的分子机制，为开发药物、疫苗或基因编辑等防控策 略提供了新靶点和新思路。（记者古一平） 记者从中国农业科学院获悉，中国农业科学院兰州兽医研究所动物免疫与代谢创新团队，近日研究揭示 了猪在感染蓝耳病病毒后容易引发细菌继发感染的关键机制，为解决这一困扰猪养殖业的世界性难题提 供了新的防控思路和药物靶点。 据介绍，猪感染蓝耳病病毒后，常常会"雪上加霜"，继发各种细菌感染，导致病情急剧恶化，病死率显 著升高，给养猪业造成巨大经济损失。然而，长期以来，业内对蓝耳病病毒如何"帮助"细菌入侵的具体 机制知之甚少。 ...

Wind数据显示，截至9月30日上午收盘，长春高新涨0.87%，报130.02元/股，最新市值为530亿元。 被称为"东北药茅"的长春高新9月29日向港交所递交H股发行上市申请。 相关业内人士表示，长春高新赴港上市，有助于其深化全球化战略布局，加快国际化进程，增强在境外的融资能力，深入挖掘公司价值，推动公司创新管 线成果持续兑现和国际化布局深入推进，打开新增长空间。 持续加大研发力度 近年来，面对行业发展趋势及公司发展需要，长春高新从技术领域着手打造产品赛道，不断提高研发效能及项目商业转化能力，快速形成创新产品矩阵并 转化为企业实际经营成果。公司积极拓展技术覆盖面，推进全球化布局，推动现有产品技术升级和工艺优化，持续完善多层次的研发管线，不断丰富项目 储备。 招股书显示，自2012年至2024年，长春高新研发费用以30.7%的复合年增长率增长。2022年、2023年、2024年及2025年上半年，公司研发费用分别占总收 入的10.8%、11.8%、16.1%及17.5%。 图片来源：Wind 产品组合日益丰富 长春高新业务覆盖治疗性生物制剂、化学药品、疫苗及中成药。公司是国内少数在上述药物类型均实现研发、生产 ...

Core Viewpoint - Changchun High-tech has submitted an application for H-share listing on the Hong Kong Stock Exchange, marking a steady progress in its overseas listing process [1] Group 1: H-share Listing and Market Context - The company has filed for H-share listing, joining a trend of A-share companies accelerating their listings in Hong Kong, with notable examples including CATL and Hengrui Medicine [1] - Hengrui Medicine has received significant recognition from overseas investors, achieving a market premium of over 10% compared to its A-share value since its H-share listing [1] Group 2: Fundraising and Strategic Transformation - The H-share issuance will be exclusively sponsored by CITIC Securities International, with the fundraising aimed at supporting clinical trials, global collaborations, enhancing sales capabilities, and general corporate purposes [2] - The fundraising aligns with the company's strategic transformation towards becoming a leading innovative global pharmaceutical company, focusing on differentiated innovation in global markets [2][3] Group 3: Product Development and Market Potential - The company is advancing its innovative drug pipeline, including the recently approved drug for acute gouty arthritis, Jinbeixin, which has shown promising clinical results [4] - The Chinese gout medication market is projected to grow from RMB 1.8 billion in 2019 to RMB 3 billion in 2024, with an expected CAGR of 17.6% until 2030, indicating significant market potential for Jinbeixin [4] Group 4: R&D and AI Integration - The company is enhancing its sales and marketing capabilities while leveraging AI technology in drug discovery and process optimization to improve research efficiency and success rates [5] - Recent collaborations, such as with Danish company ALK for allergen-specific immunotherapy products, highlight the company's commitment to expanding its product offerings and market reach [5][6]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：603609 证券简称：禾丰股份 公告编号：2025-100 债券代码：113647 债券简称：禾丰转债 禾丰食品股份有限公司 关于变更公司电子邮箱的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 禾丰食品股份有限公司（以下简称"公司"）根据实际工作需要，对公司电子邮箱进行变更，具体情况如 下： 变更前电子邮箱：hfmy@wellhope.co 变更后电子邮箱：hf@wellhopefood.com 除上述变更外，公司办公地址、联系电话等其他联系方式保持不变。变更后的电子邮箱自本公告披露之 日起正式启用，原邮箱地址同步停用，敬请广大投资者注意。由此给投资者带来的不便，敬请谅解。 特此公告。 禾丰食品股份有限公司董事会 2025年9月30日 证券代码：603609 证券简称：禾丰股份 公告编号：2025-099 债券代码：113647 债券简称：禾丰转债 禾丰食品股份有限公司 关于上海证券交易所对公司2025年半年度 报告信息披露监管问询函的回复公告 本公司董事会 ...

证 券 研 究 报 告 中牧股份（600195）2025 年中报点评 推荐（维持） 化药延续增长，经营同比改善 目标价：8.7 元 事项： ❖ 公司发布 2025 年中报：上半年实现营收 27.93 亿，同比增长 12.63%，归母净 利 8176.20 万元，同比增长 30.18%，扣非归母净利 8166.70 万元，同比增长 39.35%。 评论： ❖ 风险提示：下游景气度走弱，新品研发与推广不及预期，产品竞争加剧等。 [ReportFinancialIndex] 主要财务指标 | | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | | 营业总收入(百万) | 6,017 | 6,648 | 7,222 | 7,714 | | 同比增速(%) | 11.3% | 10.5% | 8.6% | 6.8% | | 归母净利润(百万) | 71 | 232 | 295 | 350 | | 同比增速(%) | -82.4% | 227.8% | 26.8% | 18.6% | | 每股盈利(元) | 0.07 | 0.23 | 0.2 ...

新华社北京9月28日电 题：管好心血管，警惕感染性疾病"找上门" 新华社记者李恒 9月29日是世界心脏日，今年的主题为"律动不息"。对于中老年人来说，一颗健康有力、规律跳动的心 脏，一套平稳运行的血管系统，是保障晚年生活质量的重要基础。 专家提醒，秋分过后，昼夜温差逐渐加大，心血管疾病患者，特别是免疫力较低的人群，更需注意"护 心"并警惕感染性疾病侵袭。 当前，我国心血管疾病患病人数约3.3亿，发病率随年龄增长而上升。中国医学科学院阜外医院心血管 内科主任医师高莹表示，气温波动大时，人体生理调节、血管状态及基础疾病控制都可能受到影响，易 诱发高血压急症、急性心肌梗死等血管事件。 多位专家提示，守护心脏健康，不仅需要关注血压、血脂等指标，也要防范感染性疾病的连锁影响。在 昼夜温差加大的季节，科学管理慢性病、主动预防感染，是实现"律动不息"的重要一环。 此外，寒冷环境下，中老年心血管病患者的免疫力更容易出现异常，而感染会加重体内炎症反应，进一 步干扰心血管病情的稳定控制。 以中老年人常见病带状疱疹为例，有研究表明，心血管疾病患者发生带状疱疹的风险比普通人高出 39%，且一旦发病，疼痛程度更重，持续时间更长，严重影 ...

Core Insights - The G20 Chief Scientific Advisors Roundtable and Science Ministers Meeting took place from September 21 to 24 in South Africa, serving as a significant platform for promoting technological innovation and green transformation [1] - The meeting's theme focused on "Equitable Science, Technology, and Innovation for Inclusive Human Development and Global Sustainability," emphasizing hydrogen innovation and green transition [1] Group 1: Technological Cooperation - South African experts believe that Sino-African technological cooperation is becoming a new highlight in promoting global green development [1] - South Africa is transitioning to a green economy, primarily relying on solar and wind energy, which is expected to create numerous jobs [1] - Collaboration projects exist between South African institutions and several Chinese universities in the technology sector [1] Group 2: Energy and Health Research - The South African Minister of Science and Innovation highlighted ongoing research in hydrogen energy, fuel cells, and green ammonia [1] - In the health sector, South Africa has established a foundation for vaccine production, addressing local needs [1] - There is extensive international cooperation with China across various fields, including the installation of China's Beidou navigation system in South Africa [1]